A Multicenter Randomized Open-label Study of Diammonium Glycyrrhizinate Enteric-coated Capsule Plus DXM Versus DXM in Treatment of ITP

Inclusion Criteria:

• Meet the diagnostic criteria for immune thrombocytopenia;
• Untreated hospitalized patients or patients from the clinic, may be male or female,between the ages of 18~ 80 years;
• To show a platelet count <30 * 10^9/L, or with bleeding manifestations, or both;
• Willing and able to sign written informed consent
• ITP patients with hepatitis virus infection or ITP patients with abnormal liverfunction at the time of enrollment, i.e., ITP patients with indications for diammoniumglycyrrhizinate enteric-coated capsule, should be separately stratified.

Exclusion Criteria:

• secondary thrombocytopenia;
• severe immune-deficiency;
• active or previous malignancy;
• HIV virus infection, tuberculosis, or other active infection (sepsis, pneumonia, orabscess);
• pregnancy or lactation;
• diabetes;
• hypertension;
• cardiovascular diseases;
• severe kidney function impairment;
• psychosis;
• osteoporosis;
• inflammatory bowel disease or gastric disease;
• arterial or venous thromboembolism within the 6 months before screening or patientswho required anticoagulant treatment;
• an organ or haematopoietic stem-cell transplantation;
• neutrophil count of less than 1500 cells per mm³;
• glycosylated haemoglobin less than 8%;
• partial thromboplastin time 1∙5 times or less the upper limit of normal (ULN); •clinical electrocardiogram changes;
• history of primary immunodeficiency;
• neoplastic disease within the past 5 years;
• corrected QT interval greater than 450 ms for men and greater than 470 ms for women;
• substance misuse within the previous 12 months;
• people who could not adhere to the protocol or were planning to have a surgicalprocedure in 6 months.